China Universal Asset Management Co. Ltd. Purchases 12,118 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

China Universal Asset Management Co. Ltd. lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,352 shares of the company’s stock after buying an additional 12,118 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Roivant Sciences were worth $1,826,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Gladius Capital Management LP acquired a new stake in Roivant Sciences during the 3rd quarter worth about $35,000. US Bancorp DE boosted its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares in the last quarter. GAMMA Investing LLC grew its stake in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. Quarry LP bought a new stake in Roivant Sciences in the second quarter worth approximately $53,000. Finally, Blue Trust Inc. increased its holdings in Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Insiders Place Their Bets

In related news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction dated Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CIO Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20. Following the transaction, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,980,391.35. The trade was a 2.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,942,629 shares of company stock worth $23,034,486. Insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Down 2.1 %

Shares of ROIV opened at $11.13 on Friday. The stock has a market cap of $8.10 billion, a P/E ratio of 1.97 and a beta of 1.27. The business’s fifty day moving average is $11.69 and its 200 day moving average is $11.60. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.